OBJECTIVES: Radiation-induced nausea and vomiting (RINV) is commonly experienced by cancer patients undergoing radiation treatment. Current NCCN guidelines recommend the use of the 5-hydroxytryptamine-3 serotonin receptor antagonists (5-HT3-RAs) for the prevention and treatment of RINV. The purpose of this study was to examine the incidence of 5-HT3-RA utilization and subsequent RINV, in patients diagnosed with colon cancer and undergoing radiation treatment.
OBJECTIVES:
To determine the number of patients with diagnosed acute myeloid leukaemia (AML) including chemotherapy rates, types and care settings using sickfund data. METHODS: Data provided by 4 statutory sick funds (SHI) and 2 data providers were analyzed for 2010. AML diagnosis was identified by ICD-10 C92.0 and other types of cancer by ICD-10 C00-79; D00-09; D37-48. Prevalence was extrapolated to the German population by correcting for a representative age-and gender distribution. RESULTS: The median proportion of AML patients Ͼ 60 years was 61.1% or 6,590 patients (SHI A: 63.0% ϭ 4,938; B: 50.9% ϭ 5,858; C: 68.9% ϭ 8,975). The proportion of AML patients Ͼ 65 years (sick fund D) was 47.6% or 4,400 patients. Gender ratio was 57% male and 43% female. On average, 2 additional oncological disorders were found in 77% of AML patients. 50% had an unspecified leukaemia (C95.90), 25% had CML (C92.1*) and 20% MDS (D46.9). Among patients Ͼ65 years the rate of treatment was 60.9% (Anatomical Therapeutic Chemical (ATC) Code L01* (40%), pharmacy number (PZN) 9999092 (19%), operating and procedure code (OPS) 854* (26%)). 16.4% received both out-and inpatient treatment, 34.5% received outpatient treatment and 10.0% inpatient treatment. Identification of comppunds was possible when ATC codes were reported. 63.6% received imatinib and/or hydroxycarbamide, 11.4% tioguanine, 9.1% mercaptopurine, 9.1% cytarabine and 6.8% received dasatinib. The outpatient treatment rate in patients Ͼ 60 years diagnosed with AML only was 34.3% (6,2% mercaptopurine and idarubicine, 28.1% PZN 9999092). CONCLUSIONS: Prevalence was higher than previously reported incidence numbers of 3,100 AML patients (SHI, all age groups). The yearly outpatient treatment rate was relatively low with 34.3% in patients diagnosed with AML alone. Other oncological disorders are likely to be diagnosed before AML diagnosis could be confirmed. Treatment rates increased with additional oncological disorders with the use of substances not approved for AML. OBJECTIVES: Panitumumab plus FOLFOX significantly improved progression-free survival (PFS) in patients with WT KRAS mCRC. The objective of this analysis was to use the quality-adjusted time without symptoms of disease or toxicity of treatment (Q-TWiST) method to compare quality-adjusted survival between the treatment arms. METHODS: Patients with mCRC were randomized to panitumumab plus FOLFOX or FOLFOX alone in a phase III clinical trial. For each treatment arm, the area under the survival curve, which was estimated using the Weibull distribution, was partitioned into health states: toxicity (TOX), time without symptoms of disease progression or toxicity (TWiST, i.e., PFS minus TOX), and relapse period (REL, i.e., overall survival (OS) minus PFS); and adjusted using utility weights derived from patient-reported EuroQoL 5-dimensions measures. The null hypothesis of no difference between treatment groups was tested based on the normal approximation with standard errors calculated by the bootstrap method. Sensitivity analyses were performed using the standard Q-TWiST approach with means restricted to median OS. RESULTS: Of 1,183 patients who were randomly assigned, 1,096 patients (93%) had available tumor KRAS status, of which 656 patients (60%) had WT KRAS tumors (panitumumab plus FOLFOX, nϭ325; FOLFOX alone, nϭ331) and were included in this analysis. Compared to patients treated with FOLFOX alone, the panitumumab plus FOLFOX group had significantly longer quality-adjusted PFS (8.5 versus 7.2 months, respectively; 1.3 additional quality-adjusted months; p ϭ 0.02) and quality-adjusted OS (22.4 versus 18.6 months; 3.8 additional quality-adjusted months; p ϭ 0.04). When analysis was restricted to 24 months follow-up, the Q-TWiST advantage was smaller but still significant (14.0 versus 13.0 months; 1.0 additional quality-adjusted month; p ϭ 0.04). CONCLUSIONS: This Q-TWiST analysis showed that in patients with previously untreated WT KRAS mCRC, panitumumab plus FOLFOX significantly improved the duration of the quality-adjusted survival compared with FOLFOX alone. OBJECTIVES: About a decade ago, the introduction of the tyrosine kinase inhibitor (TKI) imatinib dramatically extended the life span of chronic myeloid leukemia (CML) patients. Currently, there are several different TKIs approved for CML treatment. The goal of this study is to develop a clinical decision-analytic model for the evaluation of the comparative long-term effectiveness of first-line therapy for CML within the Austrian health care context. METHODS: We developed a Markov statetransition model for patients in the chronic-phase of CML treated with first-line TKI imatinib, dasatinib or nilotinib. Seven different strategies including different combinations of first and second-generation TKIs as well as chemotherapy or stem cell transplantation were evaluated. The model was parameterized using published trial data, data from the Austrian CML registry and from an Austrian CML expert panel. The model was analyzed as a cohort simulation over a lifelong time horizon. Health outcomes evaluated were life-years (LYs) gained and quality-adjusted life years (QALYs) gained. Deterministic and structural sensitivity analyses were performed. RESULTS: Nilotinib followed by dasatinib after failure is the most effective treatment in terms of both LYs gained (19.71 LY) and QALYs gained (17.08 QALYs). All strategies including a second-line TKI were superior compared to strategies without second-line TKI. Deterministic sensitivity analyses showed that the ranking of the strategies was mostly influenced by the duration of first-and second-line therapies. In a structural sensitivity analysis, where patients move directly from second-line TKI therapy to advanced stage of disease, strategies without second-line therapy are most effective. CONCLUSIONS: Based on our analyses results, the most clinically effective strategy is nilotinib followed by dasatinib as second-line therapy. All three TKIs are approved as first-line therapy in Austria. Our results may support clinicians and patients in their decision making. 
PCN3 QUALITY-ADJUSTED SURVIVAL IN PATIENTS WITH WILD-TYPE (WT) KRAS METASTATIC COLORECTAL CANCER (MCRC) RECEIVING FIRST-LINE THERAPY WITH PANITUMUMAB PLUS FOLFOX VERSUS FOLFOX ALONE

PCN4
PCN5 CABAZITAXEL PLUS CORTICOSTEROIDS IN COMPARISON TO CORTICOSTEROIDS ALONE FOR THE TREATMENT OF METASTATIC HORMONE REFRACTORY / CASTRATION-RESISTANT PROSTATE CANCER (MHRPC)
Schinzel
OBJECTIVES:
A combination Cabazitaxel plus Corticosteroids (CC) has been shown to prolong survival in patients with mHRPC versus Mitoxantrone plus Corticosteroids (MC) in the TROPIC study of patients with mHRPC. As there is no direct comparison CC vs. Corticosteroids (C) as requested by the German regulatory bodies we aimed to provide an indirect comparison. METHODS: A systematic search of the DIMDI database was conducted in 12/2011. Data were combined using metaanalyses and indirect comparisons ("Bucher et al. J Clin Oncol 2008"). The endpoints analysed were all cause mortality overall and in patients with or without pain and pain response (Hazard/Response Ratios with 95%-confidence intervals). RESULTS: A total of 168 potential publications resulted in three relevant studies (Berry, 2002; Kantoff, 1999; Tannock, 1996) 
PCN6 THE EVALUATION OF THE USE AND EFFECTIVENESS OF BEVACIZUMAB FOR PATIENTS WITH METASTATIC RENAL CELL CARCINOMA IN DAILY PRACTICE
de Groot S
OBJECTIVES:
Little is known about the use and effectiveness of new treatments for metastatic renal cell carcinoma (mRCC) in daily practice. In the Netherlands, this information is needed for expensive inpatient drugs to guarantee continued reimbursement. We evaluated the use and effectiveness of bevacizumab plus interferon alfa-2a (IFN) for patients with mRCC in Dutch daily practice. METHODS: A population-based registry was created to include patients newly diagnosed with mRCC from 2008-2010. These patients represent 55% of all patients in the Netherlands. Data were collected on patient and disease characteristics, treatments, dosages, treatment response, survival, adverse events and resource use. RESULTS: To date, data on 615 patients have been collected. Average age at diagnosis was 66.4 years (range: 23-93) and 66% was male. 53% of these patients received systemic therapy. The majority (83%) was treated with sunitinib, whereas sorafenib is most often used as second-line treatment. Data from 34 patients treated with bevacizumab plus IFN in the first line were collected. The dosage corresponded with the recommended dosage (10 mg/kg). Since the mean weight of patients in daily practice was higher than the mean weight seen in the phase III trial (87.5 vs 76.0 kg), the mean dosage was also higher. Of the 34 patients treated with bevacizumab plus IFN, median overall survival was similar to that seen in the phase III trial (23.0 vs 23.3 months). CONCLUSIONS: Feasibility issues come into play when evaluating the use and effectiveness of expensive inpatient drugs in daily practice. Since bevacizumab plus IFN is not regularly used in daily practice, future cost-effectiveness analyses will have to be based on a careful synthesis of evidence from daily practice, the phase III trial, quality of life studies and other sources.
PCN7 A SYSTEMATIC REVIEW OF THE HETEROGENEITY OF TREATMENT EFFECT IN OVARIAN CANCER (OC)-ARE THERE IMPLICATIONS FOR OUTCOMES RESEARCH?
Chawla 
OBJECTIVES:
Clinical studies typically assess average treatment effect on outcomes, potentially ignoring heterogeneity of treatment effect associated with phenotypic and genotypic characteristics. A paradigm shift where drugs are targeted to disease subtypes based on molecular biomarkers, rather than phenotypic or histological characteristics alone, is underway and beginning to influence outcomes research. Our objective was to assess heterogeneity of treatment effect associated with adjuvant and advanced-stage therapy for OC and strength of evidence documenting association between patient or tumor characteristics and outcomes. METHODS: We conducted a review according to the Cochrane Handbook of Systematic Reviews, with two independent reviewers completing study selection from 11 databases and data extraction on several outcomes: overall survival (OS), progression-free survival (PFS), tumor response, disease-free survival, time to progression, adverse events, and quality of life (QOL). Studies that did not evaluate characteristics identified as predictive of anti-cancer treatment outcome, regardless of whether treatment was molecularly targeted, were excluded. Descriptive analyses were conducted. RESULTS: Forty-seven of 554 publications were selected (93% concordance between reviewers). Most studies presented post-hoc analyses (45/ 47); over half evaluated platinum-taxane combinations (27/47). Fifty-three distinct patient or tumor characteristics were evaluated for association with outcomes. Nine of the 10 most frequently studied characteristics were molecular: p53, VEGF, ERCC1, CA-125, CD31-MVD, stathmin, TSP1-1A, ␤III-tubulin and CD24. No studies assessed predictive factors for QOL. Elevated CA-125 and stathmin levels were each predictive of worsening OS and PFS, and VEGF levels or genotype were mostly unrelated to OS or PFS. CONCLUSIONS: There are numerous studies that associate mostly molecular markers with traditional measures of treatment effect; however, patient-centered outcomes in this context have not yet been studied in OC. Future evaluations of treatment effect in OC should also consider variation in these patient and tumor characteristics, in addition to histological and phenotypic characteristics, for association with QOL. 
PCN8 AXITINIB (AXI) AND BEST SUPPORTIVE CARE (BSC) IN THE TREATMENT OF SUNITINIB-REFRACTORY PATIENTS WITH METASTATIC RENAL CELL CARCINOMA (MRCC): RESULTS OF A SIMULATED TREATMENT COMPARISON (STC) ANALYSES
OBJECTIVES:
To compare overall survival (OS) and progression free survival (PFS) in sunitinib-refractory (SU-r) patients with mRCC treated with AXI and BSC using STC. METHODS: STC method was used to derive OS and PFS curves for a hypothetical cohort of "AXI-like" patients had they received BSC in the AXIS trial. Patient level data on SU-r patients from the AXIS trial were used to derive predictive equations for OS and PFS. Parametric survival analysis identified the best fitting distribution and significant predictors of OS and PFS. These equations were calibrated using patient characteristics and mPFS and cross-over adjusted mOS of the BSC cohort in the RECORD-1 trial. RESULTS: In AXIS all 194 SU-r AXI patients progressed on one line of treatment. In RECORD-1 78% of BSC patients had 2ϩ prior lines and some failed 1 st line treatment due to intolerability. Other available patient characteristics were comparable except for MSKCC risk category (36% vs 15% poor risk, AXI vs BSC respectively) and ECOG score (52% vs 68% with ECOG 0). The final predictive equations using the best-fitting log-normal distribution included MSKCC risk group and age for PFS, and MSKCC risk category and duration of prior SU for OS. Median estimated OS and PFS was 15.2 and 5.1 months for AXI compared to 8.3 and 1.6 months for BSC respectively. Estimated difference in mean OS and PFS between AXI and BSC was 11.4 and 5.9 months. Sensitivity analyses using patient characteristics of the SU-r subgroup of everolimus arm and Weibull distribution showed similar results. CONCLUSIONS: The STC analysis, an alternative to mixed treatment comparison, suggested a significant improvement in OS and PFS for SU-r mRCC patients treated with AXI compared to BSC. However, the analysis could not account for all the differences between patient populations, particularly for the number of prior non-VEGFR-TKI therapies. 
PCN9 MODELING LIFETIME EFFECTIVENESS OF DENOSUMAB VERSUS PLACEBO IN MEN WITH CASTRATION RESISTANT PROSTATE CANCER (CRPC) AT HIGH RISK OF DEVELOPING BONE METASTASIS (BM)
Lothgren
OBJECTIVES:
Chemotherapy-induced nausea and vomiting (CINV) is a significant adverse effect of cancer chemotherapy treatment. The 5-hydroxytryptamine-3 receptor antagonists (5-HT3-RAs), a class of antiemetics, is indicated for the prevention and treatment of CINV. The purpose of this study was to examine the use of rescue antiemetic administration for CINV in patients diagnosed with cancer and undergoing single-day chemotherapy. METHODS: A retrospective cohort analysis using the Ingenix LabRx® database was conducted. Adult patients diagnosed with lung, breast, or colon cancer, treated with a moderately (MEC) or highly emetogenic chemotherapy (HEC), and who received a prophylactic 5-HT3-RA from 4/1/08 to 3/31/09, were identified. The outcome of interest was the rate of rescue antiemetic administration, per cycle of chemotherapy, between 5-HT3-RA treatment cohorts. Rescue antiemetic utilization was defined by a HCPCS code for administration of an antiemetic from day 2 to the end of the cycle or for 30 days following single-day chemotherapy. RESULTS A total of 5,912 patients were identified, 25.7% treated with a HEC regimen and 74.3% on a MEC regimen.The mean age was 56.1 years and 77.1% were female. Patients were treated with a total of 21,821 cycles of chemotherapy. The most common 5-HT3-RA utilized was palonosetron (73% of cycles) followed by ondansetron (11%), granisetron (10%), and dolasetron (6%). The overall unadjusted rate of rescue antiemetic administration per cycle was 17.6%, and the rate differed by 5-HT3-RA utilized. Patients treated with palonosetron were significantly less likely to require a rescue antiemetic on a per cycle basis (14.1%), compared to patients treated with another 5-HT3-RA (26.6%), pϽ.001.
CONCLUSIONS:
The results from this retrospective analysis suggest that rescue antiemetic utilization may be significantly reduced in patients undergoing chemotherapy following use of palonosetron vs. another 5-HT3-RA for the prevention of CINV.
